{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:53:13Z","timestamp":1790974393933,"version":"4.1.0"},"reference-count":46,"publisher":"American Society of Clinical Oncology (ASCO)","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"abstract":"<jats:p>Cachexia is a multifactorial syndrome characterized by systemic inflammation, weight loss, and muscle wasting, affecting over 80% of patients with pancreatic cancer. It decreases treatment tolerance, quality of life, and survival. Yet, despite its well-recognized detrimental impact, cachexia remains underdiagnosed and undertreated in oncology clinics. This review synthesizes current understanding of pancreatic cancer cachexia with an emphasis on its complex pathophysiology involving inflammatory cytokines, tumor-derived catabolic factors, neuroendocrine disruption, and pancreatic insufficiency as advancing insight into these underlying mechanisms is driving the development of targeted therapies for cachexia. A narrative review of the literature was performed using PubMed, Embase, and Google Scholar to identify studies related to pancreatic cancer cachexia. Relevant peer-reviewed clinical trials, translational studies, and review articles focusing on pathophysiology, nutritional assessment, and management strategies were prioritized. Emerging therapeutic strategies targeting the underlying biology of cachexia, including growth differentiation factor-15 inhibition, inflammatory pathway blockade, and ghrelin receptor agonism, have demonstrated encouraging effects on weight, muscle preservation, appetite, and functional measures. Advances in nutritional assessment, body composition analysis, and biomarker development may further improve early detection and management. Pancreatic cancer cachexia should be recognized as an active and potentially modifiable process rather than an inevitable consequence of advanced disease. Earlier identification, multidisciplinary management, and emerging mechanism-based therapies may improve clinical outcomes and quality of life for patients with pancreatic cancer.<\/jats:p>","DOI":"10.1200\/op-26-00673","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:59:07Z","timestamp":1790971147000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Pancreatic Cancer Cachexia: Integrating Mechanistic Insights With Clinical Management"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9333-4808","authenticated-orcid":true,"given":"Lyndon","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, The University of Texas at Austin, Austin, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2166-4303","authenticated-orcid":true,"given":"Valeria","family":"Impedovo","sequence":"additional","affiliation":[{"name":"Department of Nutritional Sciences, The University of Texas at Austin, Austin, TX"},{"name":"Dell Pediatric Research Institute, Dell Medical School, The University of Texas at Austin, Austin, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Tiziani","sequence":"additional","affiliation":[{"name":"Department of Nutritional Sciences, The University of Texas at Austin, Austin, TX"},{"name":"Dell Pediatric Research Institute, Dell Medical School, The University of Texas at Austin, Austin, TX"},{"name":"Department of Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, TX"},{"name":"Division of Oncology, University of Texas at Austin Cancer Research Center, Dell Medical School, The University of Texas at Austin, Austin, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2153-3896","authenticated-orcid":true,"given":"Sarbajit","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Baptist Health Herbert Wertheim Cancer Institute, Baptist Health South Florida, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Cristian","sequence":"additional","affiliation":[{"name":"Department of Cancer Patient Support Services, Baptist Health Herbert Wertheim Cancer Institute, Baptist Health South Florida, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9889-0379","authenticated-orcid":true,"given":"Kyaw","family":"Aung","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Baptist Health Herbert Wertheim Cancer Institute, Baptist Health South Florida, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/PL00012351"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70218-7"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-021-00582-2"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/MCO.0000000000000815"},{"key":"e_1_3_4_6_2","first-page":"167","article-title":"Sarcopenia and cachexia evaluation in different healthcare settings: A questionnaire survey of health professionals","volume":"27","author":"Nakahara S","year":"2018","unstructured":"Nakahara S, Wakabayashi H, Maeda K, et al: Sarcopenia and cachexia evaluation in different healthcare settings: A questionnaire survey of health professionals. Asia Pac J Clin Nutr 27:167-175, 2018","journal-title":"Asia Pac J Clin Nutr"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102717"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/2050640620938987"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2023.2194489"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1625114"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16091709"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2014.00088"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.3390\/nu12061543"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602780"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1332"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2023.101729"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12461"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194842"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101441"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/nu15010050"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/jhn.70012"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2023.1116243"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1079\/BJN20041258"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2017.11.10"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2015.07.022"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13685"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11092356"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12378-4"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13041"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/MCO.0b013e32832a7902"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094501"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2025.167684"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13321"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/jpen.2688"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2018.08.002"},{"key":"e_1_3_4_36_2","first-page":"322","article-title":"Effectiveness of the nutrition referral system in a multidisciplinary pancreatic cancer clinic","volume":"31","author":"Wong SC","year":"2023","unstructured":"Wong SC, Reddy AV, Hacker-Prietz A, et al: Effectiveness of the nutrition referral system in a multidisciplinary pancreatic cancer clinic. Support Care Cancer 31:322, 2023","journal-title":"Support Care Cancer"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153816"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/jpen.2364"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00611"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409515"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01965"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-19401-3"},{"key":"e_1_3_4_43_2","volume-title":"IIT2021-16-Hendifar-KetoROCX: A Feasibility Study of Ketorolac Treatment for Cachexia in Patients with Advanced Pancreatic Ductal Adenocarcinoma. clinicaltrials.gov","author":"Hendifar A","year":"2025","unstructured":"Hendifar A: IIT2021-16-Hendifar-KetoROCX: A Feasibility Study of Ketorolac Treatment for Cachexia in Patients with Advanced Pancreatic Ductal Adenocarcinoma. clinicaltrials.gov. 2025. https:\/\/clinicaltrials.gov\/study\/NCT05336266"},{"key":"e_1_3_4_44_2","volume-title":"A Randomized, Double-Blind, and Placebo Controlled Multicenter Phase II Trial Evaluating Anamorelin in the Prevention of Cancer Induced-Weight Loss and Anorexia in Patients Receiving First-Line Treatment of Advanced Pancreatic Cancer. clinicaltrials.gov","author":"Lahey Clinic","year":"2024","unstructured":"Lahey Clinic: A Randomized, Double-Blind, and Placebo Controlled Multicenter Phase II Trial Evaluating Anamorelin in the Prevention of Cancer Induced-Weight Loss and Anorexia in Patients Receiving First-Line Treatment of Advanced Pancreatic Cancer. clinicaltrials.gov. 2024. https:\/\/clinicaltrials.gov\/study\/NCT04844970"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00558-6"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-008-0505-z"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100092"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-26-00673","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:59:09Z","timestamp":1790971149000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-26-00673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":46,"alternative-id":["10.1200\/OP-26-00673"],"URL":"https:\/\/doi.org\/10.1200\/op-26-00673","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"assertion":[{"value":"2026-05-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"OP-26-00673"}}